Research Output per year
Fingerprint Dive into the research topics where Sven Stegemann is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 4 Similar Profiles
Dosage Forms
Medicine & Life Sciences
Polymers
Medicine & Life Sciences
Pharmaceutical Preparations
Medicine & Life Sciences
Deglutition
Medicine & Life Sciences
Safety
Medicine & Life Sciences
Excipients
Medicine & Life Sciences
Mucins
Medicine & Life Sciences
Population
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Research Output 2005 2018
EMA : Die Expertise der Apotheker ist gefragt.
Stegemann, S., 1 Jan 2018, In : Österreichische Apotheker-Zeitung. 72, 1, p. 60-62 3 p.Research output: Contribution to journal › Article › Research
Ensuring parenteral biologics’ quality and safety
Stegemann, S., 1 Jul 2018, In : AAPS Newsmagazine. 7, p. 12-17 5 p.Research output: Contribution to journal › Article › Research › peer-review
Formulation and methodological assessment of patient centric technologies for solid oral dosage forms (SODF)
Drumond, N. & Stegemann, S., 22 Mar 2018.Research output: Contribution to conference › Poster › Research › peer-review
Open Access
File
Hard capsules in modern drug delivery
Stegemann, S., 1 Oct 2018, Pharmaceutical Formulation: The Science and Technology of Dosage Forms. 1 ed. Cambridge (UK), Vol. 63. p. 21-51 30 p.Research output: Chapter in Book/Report/Conference proceeding › Chapter › Research › peer-review
Improving therapeutics to better care for older adults and the young: Report from an American College of Clinical Pharmacology workshop
Lau, S. W. J., Schlender, J. F., Abernethy, D. R., Burckart, G. J., Golden, A., Slattum, P. W., Stegemann, S. & Eissing, T., 31 Jan 2018, In : The journal of clinical pharmacology. 58, 3, p. 277-280 4 p.Research output: Contribution to journal › Article › Research › peer-review
Activities 2008 2016
From ‘me-too’ to ‘added value me too’ to ‘enhanced therapeutic’ (“supergeneric”): A way to create competitive advantages in the generic business
Sven Stegemann (Speaker)22 Apr 2016
Activity: Talk or presentation › Invited talk › Science to science
Opportunities for generic developers
Sven Stegemann (Speaker)27 Jan 2016
Activity: Talk or presentation › Invited talk › Science to science
Investigating and selecting the optimal capsule based on capsule-formulation and device-capsule interaction to improve product performance.
Sven Stegemann (Speaker)1 Mar 2016
Activity: Talk or presentation › Invited talk › Science to science
Taking a fresh look to multiparticulates in the Age of Patient centric product design
Sven Stegemann (Speaker)22 Sep 2016
Activity: Talk or presentation › Invited talk › Science to science
Aus Patientensicht: Zwischen erleben, verstehen und einnehmen
Sven Stegemann (Speaker)6 Mar 2016
Activity: Talk or presentation › Invited talk › Science to science
Projects 2014 2019
- 2 Finished
SV-PCPL - SV-PatientcentricProductLab - Patient Centric Drug Product Design & Manufacturing
Stegemann, S. & Drumond Freitas, N. D.
1/01/16 → 1/07/16
Project: Research project